Akinchan Bhardwaj: Exercise Biological Modifier of Vascular Trajectory
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn:
“If exercise were a drug, we would call it multi-target vascular therapy.
Exercise is often framed as ‘cardiovascular risk reduction.’ But that description undersells what it actually does.
Exercise is not simply a statistical modifier of event probability.
It is a biological modifier of vascular trajectory.
Regular physical activity has been shown to:
- Improve endothelial nitric oxide bioavailability
- Reduce systemic inflammatory tone
- Enhance insulin sensitivity independent of weight loss
- Improve autonomic balance and blood pressure variability
- Influence plaque phenotype toward more stable morphology
Most pharmacologic therapies act on a single pathway.
Exercise simultaneously influences lipid metabolism, inflammation, metabolic pressure and vascular function.
If cardiovascular risk is a curve, exercise does not just shift it downward. It reduces its slope.
That distinction matters as we rethink prevention in an era of genomics, AI and precision risk modeling.
I explore this in my latest CardioForesight essay:
‘Exercise Doesn’t Just Lower Risk, It Changes Vascular Biology.'”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 11:50Guy Young: Clinical Conversations on Gene Therapy Progress in Hemophilia B at THSNA 2026
-
Mar 12, 2026, 11:44Yves Bikorimana: Causes, Diagnosis, and Management of Neonatal Alloimmune Thrombocytopenia
-
Mar 12, 2026, 11:33Kymentie Ferdinande: New Insights Into Platelet Function and Thrombus Formation in Cirrhosis
-
Mar 12, 2026, 11:17Tareq Abadl: Why Do Some People Bruise And Bleed So Easily?
-
Mar 12, 2026, 11:15Matthew Flick: The Interplay of the Fibrinogen αC-Region, Hypofibrinogenemia, and GPVI in Arterial Thrombosis
-
Mar 12, 2026, 11:08Stephen Twumasi: The Impact of Hepatitis B Infection on the Coagulation System During Pregnancy
-
Mar 12, 2026, 11:05Robert Lufkin: One Minute of Wisdom from Robert Lustig on Cholesterol, Sugar, and Heart Disease
-
Mar 12, 2026, 10:36Cynthia Dunbar: Retiring From NIH After 39 Years to Advance Advocacy and Research in Hematology
-
Mar 11, 2026, 23:05Ney Carter Borges: A Safety Advantage of Apixaban over Rivaroxaban Without Clear Superiority